Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study Posted byZacks Equity Research September 9, 2021 Leave a comment on Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study Sanofi’s (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Princ…